We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ADVANC:SETAdvanced Info Service Public Co., Ltd. Analysis

Data as of 2026-06-19 - not real-time

$537.37

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Advanced Micro Devices (AMD) is trading at a striking $537.37, well above its DCF fair value of $163, indicating a substantial premium. The stock sits comfortably above its 20‑day, 50‑day and 200‑day SMAs (≈$502, $411 and $261 respectively) and the 30‑day volatility is soaring above 80%, reflecting a very active market. Technical momentum remains bullish with a trend direction flagged as bullish and an RSI of 61, yet the MACD histogram is negative and the signal line is bearish, suggesting short‑term pressure near the resistance level of $558. Revenue growth is robust at 38% YoY, and margins stay healthy (gross ~53%, operating ~14%). However, the trailing P/E of 180 dwarfs the industry average of 38, and the forward P/E of 41 still signals significant overvaluation. The balance sheet shows ample cash ($12.3 B) versus modest debt ($3.9 B), but the debt‑to‑equity ratio of 6.0 flags leverage concerns. Analyst consensus leans strongly bullish (strong buy) but the price already reflects much of the upside, leaving limited near‑term upside potential.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price hovering near 52‑week high with limited upside to resistance
  • Bearish MACD crossover despite overall bullish trend
  • RSI in moderate range indicating no immediate overbought condition

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Fundamentals showing strong revenue growth and cash generation
  • Extreme valuation premium (P/E ~180 vs industry ~38)
  • High beta (≈2.9) and volatility amplifying price swings

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Secular AI and data‑center demand driving product tailwinds
  • Solid balance sheet with ample cash and manageable debt
  • Long‑term earnings expansion potential outweighing current overvaluation

Key Metrics & Analysis

Financial Health

Revenue Growth37.80%
Profit Margin13.37%
P/E Ratio179.7
ROE8.06%
ROA3.65%
Debt/Equity6.00
P/B Ratio13.6
Op. Cash Flow$9.7B
Free Cash Flow$7.2B
Industry P/E38.1

Technical Analysis

TrendBullish
RSI61.2
Support$431.60
Resistance$558.37
MA 20$501.86
MA 50$411.05
MA 200$261.15
MACDBearish
VolumeStable
Fear & Greed Index92.14

Valuation

Fair Value$163.62
Target Price$487.90
Upside/Downside-9.21%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta2.88
Volatility80.21%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.